Probiotic and prebiotic composition and application thereof in preparation of products for preventing obesity

Through the composition of xylooligosaccharides and isomaltose oligosaccharides and Lactobacillus fermentation technology, the problem of unpredictable effects of single oligosaccharides in obesity prevention is solved, and significant anti-obesity and blood lipid improvement effects are achieved. To prevent health problems such as obesity and hyperlipidemia.

CN118947909AActive Publication Date: 2024-11-15JIANGNAN UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411061947.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-05
Publication Date
2024-11-15
Estimated Expiration
2044-08-05

AI Technical Summary

Technical Problem

A single type of non-digestible oligosaccharide has limitations in the prevention and treatment of obesity, making it difficult to predict and control its effect in different populations, and the combination increases the complexity and difficulty of production of products, resulting in lower results than expected. .

Method used

The composition of xylooligosaccharide and isomaltose isomaltosaccharide is used, and the mass ratio and viable bacteria are adjusted through Lactobacillus johnson to improve the anti-obesity effect, and is used to prepare the prevention of obesity, non-alcoholic fatty liver, high Blood lipids and other products.

Benefits of technology

Significantly inhibited the weight gain of mice induced by high-fat diet, improved blood lipid levels, decreased total cholesterol and triglycerides, increased high-density lipoprotein cholesterol, improved fat ectopic deposition and liver weight, significantly regulated intestinal microbial community structure, and enhanced probiotics The proliferation effect of bacteria.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118947909A_ABST
    Figure CN118947909A_ABST
Patent Text Reader

Abstract

The invention relates to a probiotic and prebiotics composition and application thereof in preparation of a product for preventing obesity, the probiotics comprise lactobacillus johnsonii, and the prebiotics comprise xylooligosaccharide and isomaltooligosacharide in a mass ratio of (0.5-2.5): (0.5-2.5). The probiotics and the prebiotics in the composition have a synergistic effect, can inhibit weight gain of high-fat diet mice, improve the blood fat level of the high-fat diet mice, reduce total cholesterol, triglyceride or low-density lipoprotein cholesterol in serum of the mice, increase high-density lipoprotein cholesterol in the serum, improve ectopic deposition of fat and improve the immunity of the mice. The weight of the liver and epididymis fat is reduced, and the compound can be applied to preparation of food or medicines for preventing obesity or preventing non-alcoholic fatty liver, has a wide application prospect, and provides a brand new idea for prevention or treatment of obesity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of food medicine, in particular to a probiotic-prebiotic composition and an application thereof in preparing a product for preventing obesity. Background Art

[0002] Obesity is a chronic and complex metabolic disease characterized by excessive accumulation of body fat. When the calories consumed by the human body exceed the calories consumed, the excess calories will be stored in the body in the form of fat. When the amount of fat accumulated exceeds the normal physiological needs and reaches a certain value, it will develop into obesity. Obesity not only affects the appearance and self-confidence of an individual, but is also closely related to health problems. Since 1990, the global adult obesity rate has doubled, while the adolescent obesity rate has increased fourfold. Obesity has become one of the most serious public health problems worldwide. Obesity not only has a serious impact on personal health, but also has negative effects on socioeconomic and psychological levels. Therefore, the prevention and treatment of obesity is of great significance to improving the overall health level of human society and reducing the medical burden.

[0003] According to the consensus statement of the International Scientific Association for Probiotics and Prebiotics (ISAPP), substrates that can be selectively utilized by host microorganisms and can confer health benefits to the host are called prebiotics. Among them, non-digestible oligosaccharides are composed of 2-10 sugar units connected by glycosidic bonds and are an important type of prebiotics.

[0004] Nevertheless, there are still many problems in applying non-digestible oligosaccharides to the prevention and treatment of obesity. Although a single type of non-digestible oligosaccharide may show significant prebiotic effects in specific aspects, its effects are often limited. Long-term intake of the same type of oligosaccharide alone may lead to an imbalance in the structure of the intestinal flora, which in turn affects its long-term benefits. In addition, there are differences in the composition and metabolic capacity of intestinal microorganisms between different individuals, which also makes it difficult to predict and unify the effects of a single oligosaccharide in different populations. In order to overcome the limitations of single oligosaccharides and enhance their anti-obesity effects, more and more studies have begun to focus on the compound use of non-digestible oligosaccharides in recent years. The compounding strategy aims to achieve more comprehensive intestinal health regulation and more significant anti-obesity effects through the complementary effects of different types of oligosaccharides.

[0005] However, there are many types of non-digestible oligosaccharides, and each oligosaccharide has different structures, molecular weights, solubility, and metabolic pathways in the intestine, which results in specific effects on the intestinal microbial community. The compounding of multiple non-digestible oligosaccharides will significantly increase the complexity of the product formulation, so these factors need to be carefully considered during the compounding process to ensure the overall quality and stability of the product. This complexity may increase the difficulty of production and supervision, while also increasing production costs. Although the original intention of compounding is to achieve synergistic effects, the interaction mechanism between different oligosaccharides has not yet been fully elucidated. Therefore, in practical applications, it is difficult to accurately predict and control the specific effects of compound products on intestinal microbial communities, metabolic pathways, and human health. This uncertainty may cause the effect of compound products to be less than expected. Summary of the invention

[0006] In order to solve the above technical problems, the present invention provides a composition of probiotics and prebiotics and its application in the preparation of obesity prevention products. The present invention explores the anti-obesity effects of different non-digestible oligosaccharide combinations, and determines the best non-digestible oligosaccharide combination by adjusting the ratio, that is, the combination of xylooligosaccharides and isomaltooligosaccharides, and then further uses intestinal probiotics Lactobacillus johnsonii to ferment the composition of xylooligosaccharides and isomaltooligosaccharides, and verifies that the fermentation product further enhances the anti-obesity effect.

[0007] The first object of the present invention is to provide a composition of probiotics and prebiotics, wherein the probiotics include Lactobacillus johnsonii, and the prebiotics are xylooligosaccharides and isomaltooligosaccharides, and the mass ratio of the xylooligosaccharides to isomaltooligosaccharides is (0.5-2.5):(0.5-2.5).

[0008] Furthermore, the mass ratio of xylooligosaccharide to isomaltooligosaccharide is (0.5-1.5):(1.5-2.5).

[0009] Preferably, the mass ratio of xylooligosaccharides to isomaltooligosaccharides is 1:2.

[0010] Furthermore, the viable count of Lactobacillus johnsonii is (1-5)×10 5 CFU / mL.

[0011] Preferably, the viable count of Lactobacillus johnsonii is 1×10 5 CFU / mL.

[0012] The second object of the present invention is to provide the use of the above composition in preparing products for preventing obesity.

[0013] Furthermore, the obesity is obesity induced by a high-fat diet.

[0014] Furthermore, the obesity prevention product is food or medicine.

[0015] Furthermore, the food includes health food and special medical purpose formula food.

[0016] The third object of the present invention is to provide a special medical formula food for preventing obesity, comprising the above composition.

[0017] Furthermore, it also includes food-acceptable auxiliary materials.

[0018] The fourth object of the present invention is to provide a drug for preventing obesity, comprising the above composition.

[0019] Furthermore, the drug is taken in through the digestive tract.

[0020] Furthermore, the drug is in the form of tablets, capsules, water pills, granules, powders or oral liquids.

[0021] The fifth object of the present invention is to provide the use of the above composition in preparing a product for preventing non-alcoholic fatty liver disease.

[0022] The sixth object of the present invention is to provide the use of the above composition in the preparation of products for preventing hyperlipidemia.

[0023] The seventh object of the present invention is to provide the use of the above composition in the preparation of a product for increasing high-density lipoprotein cholesterol in serum.

[0024] The eighth object of the present invention is to provide the use of the above composition in the preparation of a product for reducing total cholesterol, triglycerides or low-density lipoprotein cholesterol in serum.

[0025] Beneficial effects of the present invention:

[0026] The probiotic and prebiotic composition provided by the present invention can inhibit the weight gain of mice fed a high-fat diet, improve the blood lipid level of mice fed a high-fat diet, reduce the total cholesterol, triglycerides or low-density lipoprotein cholesterol in the serum of mice, and increase the high-density lipoprotein cholesterol in the serum. At the same time, the composition can improve the ectopic deposition of fat, reduce the weight of the liver and epididymal fat, and inhibit the expansion of white fat cells and the whitening of brown fat cells. Compared with mice fed a high-fat diet, the combination of xylooligosaccharides and isomaltooligosaccharides upregulated the expression levels of stearoyl-CoA desaturase 1 (Scd1) and peroxisome-activated receptor α (Pparα) mRNA in the liver, which was beneficial to the oxidative decomposition of fatty acids, promoted the production of acetic acid and propionic acid by intestinal microorganisms in mice fed a high-fat diet, restructured the intestinal microbial community structure of mice fed a high-fat diet, and significantly upregulated the abundance of Lactobacillus and Lactobacillus johnsonii. Therefore, the composition has a significant synergistic effect. Prebiotics can promote the proliferation of probiotics, and the efficacy of prebiotics is further enhanced under the action of probiotics. It can be used to prepare foods or drugs for preventing obesity and hyperlipidemia, and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] In order to make the content of the present invention more clearly understood, the present invention is further described in detail below according to specific embodiments of the present invention in conjunction with the accompanying drawings, wherein

[0028] Figure 1 is the anti-obesity efficacy evaluation of the non-digestible oligosaccharide composition in Example 2 of the present invention after 12 weeks of dietary intervention on mice, wherein AD is the weight change of mice, E is the energy intake of mice, F is the liver weight of mice, GJ are the levels of total cholesterol, triglycerides, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in the serum of mice, respectively, and K is the epididymal fat weight of mice;

[0029] Figure 2 is the regulatory effect of the non-digestible oligosaccharide composition on lipid metabolism in mice after 12 weeks of dietary intervention in Example 3 of the present invention, wherein A is white adipose tissue, B is brown adipose tissue, C is liver tissue, and D is the mRNA expression level related to lipid metabolism in the liver of mice;

[0030] Figure 3 is the regulatory effect of the non-digestible oligosaccharide composition in Example 4 of the present invention on the intestine after 12 weeks of dietary intervention on mice, wherein A is the content of short-chain fatty acids, B is the principal component analysis diagram of the intestinal flora of mice, C is the abundance of Lactobacillus, and D is the abundance of Lactobacillus johnsonii;

[0031] Figure 4This is the anti-obesity efficacy evaluation of the xylooligosaccharide and isomaltooligosaccharide compositions of different ratios in Example 6 of the present invention on mice after 12 weeks of dietary intervention, wherein A is the weight change of the mice, and B is the energy intake of the mice. DETAILED DESCRIPTION

[0032] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.

[0033] Example 1: Dietary intervention strategy of non-digestible oligosaccharide composition

[0034] The temperature of the feeding room for 54 C57BL / 6J mice was 20-26℃, the relative humidity was 40-70%, the noise was less than 60dB, the animal illumination was 15-20lx, and the light cycle was 12h light and 12h dark cycle. Functional oligosaccharides of different types and formulations were used for dietary intervention. To ensure the energy of the feed in all groups was consistent, 3% of non-digestible oligosaccharides were used to replace the dietary fiber in the high-fat diet (HFD) feed. All mice were randomly divided into the following 9 groups, 6 in each group. The feed formula ingested by each group of mice is shown in Table 1, where " / " means no addition:

[0035] (1) Standard diet (Chow) group;

[0036] (2) high-fat diet (HFD) group;

[0037] (3) high-fat diet + 3% xylo-oligosaccharide (HFD+XOS) group;

[0038] (4) high-fat diet + 3% galacto-oligosaccharides (HFD+GOS) group;

[0039] (5) high-fat diet + 3% isomaltooligosaccharide (HFD+IMO) group;

[0040] (6) high-fat diet + 1.5% xylooligosaccharides + 1.5% galacto-oligosaccharides (HFD+XOS+GOS) group;

[0041] (7) high-fat diet + 1.5% xylooligosaccharides + 1.5% isomaltooligosaccharides (HFD+XOS+IMO) group;

[0042] (8) high-fat diet + 1.5% galacto-oligosaccharide + 1.5% isomaltooligosaccharide (HFD+GOS+IMO) group;

[0043] (9) High-fat diet + 1% xylooligosaccharides + 1% galacto-oligosaccharides + 1% isomaltooligosaccharides (HFD+XOS+GOS+IMO) group.

[0044] Table 1 Experimental feed formula

[0045]

[0046]

[0047] Example 2: Evaluation of the anti-obesity efficacy of non-digestible oligosaccharide compositions

[0048] Different types and ratios of functional oligosaccharides were used to intervene in the diet of mice fed HFD for 12 weeks. Figure 1 B shows that compared with mice fed an HFD diet, the addition of XOS and IMO combination to the HFD feed significantly inhibited the weight gain of mice starting from the 8th week of dietary intervention. After 12 weeks of feeding, the weight loss of mice in the HFD+XOS+IMO group was 10.80% lower than that of the HFD group, while the addition of XOS or IMO alone to the feed could not achieve this effect, and there was no significant difference in energy intake among all mice except the Chow group ( Figure 1 E), indicating that the combination of XOS and IMO can synergistically inhibit the weight gain of mice induced by HFD diet. In addition, after 12 weeks of dietary intervention, the liver weight of the HFD+XOS+IMO group was reduced by 18.58% compared with the HFD group ( Figure 1 F), epididymal fat weight decreased by 18.33% ( Figure 1 K). The non-digestible oligosaccharide composition can improve the blood lipid level of HFD mice. Compared with the HFD group, the serum low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) levels of mice in the HFD+XOS+IMO group were reduced by 24.79% and increased by 34.43%, respectively ( Figure 1 I and Figure 1 J).

[0049] Example 3: Evaluation of the efficacy of non-digestible oligosaccharide composition in improving lipid metabolism

[0050] The HFD+XOS+IMO group was able to improve the pathological histomorphology of white adipose tissue, brown adipose tissue, and liver tissue by using a single type and a combination of non-digestible oligosaccharides to intervene in the diet of mice fed HFD for 12 weeks. Compared with mice fed a high-fat diet, the HFD+XOS+IMO group could inhibit the accumulation of triglycerides in white and brown adipocytes, inhibit the enlargement of white adipocytes and the whitening of brown adipocytes ( Figure 2 A and 2B). At the same time, the HFD+XOS+IMO group could alleviate the fatty infiltration in the liver of mice fed a high-fat diet, thereby alleviating the occurrence of non-alcoholic fatty liver disease ( Figure 2C). Real-time fluorescence quantitative PCR was used to analyze the mRNA expression of lipid metabolism-related genes, including Cd36 (fatty acid transporter), Pparγ (peroxisome-activated receptor γ), Acc1 (acetyl-CoA carboxylase), Fasn (fatty acid synthase), Srebp1c (sterol regulatory element binding protein), Scd1 (stearoyl-CoA desaturase 1), Cpt1a (carnitine palmitoyltransferase 1a), and Pparα (peroxisome-activated receptor). The results are shown in Figure 2. Figure 2 D. Compared with mice fed a high-fat diet, the combination of xylooligosaccharides and isomaltooligosaccharides upregulated the mRNA expression levels of stearoyl-CoA desaturase 1 (Scd1) and peroxisome-activated receptor α (Pparα) in the liver, which was beneficial to the oxidative decomposition of fatty acids.

[0051] Example 4: Non-digestible oligosaccharide composition modulates intestinal microflora

[0052] The mice fed HFD were given a single type of oligosaccharide and a combination of non-digestible oligosaccharides for 12 weeks, and the content of short-chain fatty acids in the cecum of the mice was measured. Figure 3 A shows that the concentrations of acetic acid and propionic acid in the cecal contents of mice in the HFD group were 29.94 μmol / g and 9.70 μmol / g, respectively, while the concentrations of acetic acid and propionic acid in the HFD+XOS+IMO group increased to 37.95 μmol / g and 18.32 μmol / g, respectively, and the addition of XOS or IMO alone to the feed could not achieve this effect. Acetic acid produced by the intestinal microbiota can be used as an adjuvant therapy for the management of metabolic syndrome by changing the metabolism of taurine-conjugated bile acids, and propionic acid affects the pathway of fatty acid metabolism in the liver by regulating the activity of transporters. Principal component analysis of the microbial flora in the mouse intestine was performed, and the results are as follows: Figure 3 As shown in B, the HFD+XOS+IMO group changed the intestinal microbial community structure of mice fed a high-fat diet. Further analysis of the intestinal microbial flora revealed that the abundance of Lactobacillus spp. in the HFD+XOS+IMO group was significantly upregulated, with the relative abundance increasing from 4.26% to 13.48% ( Figure 3 C), among which the abundance of Lactobacillus johnsonii increased most significantly, from 2.33% to 10.87% ( Figure 3 D).

[0053] Example 5: Dietary intervention strategies of xylooligosaccharides and isomaltooligosaccharides with different ratios

[0054] The temperature of the feeding room for 24 C57BL / 6J mice was 20-26℃, the relative humidity was 40-70%, the noise was less than 60dB, the animal illumination was 15-20lx, and the light cycle was 12h light and 12h dark cycle. Different ratios of xylooligosaccharides and isomaltooligosaccharides were used for dietary intervention. In order to ensure the energy of the feed in all groups was consistent, 3% xylooligosaccharides and isomaltooligosaccharides were used to replace the dietary fiber in the HFD feed in equal amounts. All mice were randomly divided into the following 4 groups, each with 6 mice. The feed formula ingested by each group of mice is shown in Table 1:

[0055] (1) High-fat diet + 1% xylooligosaccharides + 2% isomaltooligosaccharides (HFD + 1% XOS + 2% IMO) group;

[0056] (2) high-fat diet + 2% xylooligosaccharides + 1% isomaltooligosaccharide (HFD + 2% XOS + 1% IMO) group;

[0057] (3) high-fat diet + 0.5% xylooligosaccharide + 2.5% isomaltooligosaccharide (HFD + 0.5% XOS + 2.5% IMO) group;

[0058] (4) High-fat diet + 2.5% xylooligosaccharides + 0.5% isomaltooligosaccharides (HFD + 2.5% XOS + 0.5% IMO) group.

[0059] Table 2 Experimental feed formula

[0060]

[0061]

[0062] Example 6: Evaluation of the anti-obesity efficacy of xylooligosaccharides and isomaltooligosaccharides in different ratios

[0063] Different ratios of xylooligosaccharides and isomaltooligosaccharides were used to intervene in the diet of mice fed HFD for 12 weeks. Figure 4 B It can be seen that during the dietary intervention, the energy intake of each group of mice was equivalent. Compared with the HFD+1.5%XOS+1.5%IMO group (data from Example 2), the HFD+1%XOS+2%IMO group and the HFD+0.5%XOS+2.5%IMO group had a more positive effect on combating obesity, among which the HFD+1%XOS+2%IMO group had the most obvious effect. After 12 weeks of dietary intervention, the body weight of the HFD+1%XOS+2%IMO group decreased by 6.41% ( Figure 4A), serum total cholesterol, triglyceride, LDL-C levels decreased by 8.24%, 4.51%, 26.90%, respectively, and HDL-C level increased by 8.04%, liver and epididymal fat weight decreased by 8.57% and 16.24%, respectively (Table 3).

[0064] Table 3 Anti-obesity effects of different ratios of xylooligosaccharides and isomaltooligosaccharides

[0065]

[0066]

[0067] Example 7: Probiotic fermentation functional oligosaccharide composition

[0068] MRS medium without adding glucose was used as the basal medium. The medium formula was: 10.0 g of peptone, 10.0 g of beef extract powder, 4.0 g of yeast extract powder, 2.0 g of anhydrous sodium acetate, 2.0 g of diammonium citrate, 2.6 g of dipotassium hydrogen phosphate trihydrate, 0.1 g of magnesium sulfate heptahydrate, 0.05 g of manganese sulfate monohydrate, 1.0 g of Tween, and 0.5 g of L-cysteine ​​hydrochloride. The above ingredients were added to distilled water, the volume was adjusted to 900 mL, the pH was adjusted to 6.2-6.4, and the medium was sterilized at 121° C. for 20 min.

[0069] 100 mL of 0.2 g / mL xylooligosaccharide and isomaltooligosaccharide solution filtered through a 0.22 μm water system membrane was added to the MRS medium as a carbon source, and the final concentration of the xylooligosaccharide and isomaltooligosaccharide composition in the fermentation broth was 20 g / L. Lactobacillus johnsonii in the logarithmic growth phase was added to the culture broth for fermentation of the xylooligosaccharide and isomaltooligosaccharide composition, and the concentration of Lactobacillus johnsonii in the initial fermentation broth was adjusted to 10 5 CFU / mL, 37°C, anaerobic culture for 24 hours. After the fermentation period, the fermentation broth was centrifuged at 5000rpm for 15 minutes, the culture supernatant was collected, vacuum freeze-dried for 48 hours, and the fermentation product was obtained and gavaged to C57BL / 6J mice fed a high-fat diet at 0.4 mg / kg of mouse body weight, once every 2 days for 12 weeks.

[0070] Lactobacillus johnsonii was used to ferment xylooligosaccharides and isomaltooligosaccharides of different ratios. C57BL / 6J mice were fed a high-fat diet and ingested the fermentation products for 12 weeks. According to Table 4, the fermentation products of xylooligosaccharides and isomaltooligosaccharides can further improve the anti-obesity effect, among which the effect of the HFD+1%XOS+2%IMO group was the most obvious. In addition, the serum lipid levels of the HFD+1%XOS+2%IMO group were also closer to normal values, with total cholesterol, triglycerides, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol levels of 6.63, 1.21, 1.25, and 4.19 mmol / L, respectively.

[0071] Table 4 Anti-obesity effects of probiotic fermentation products of xylooligosaccharides and isomaltooligosaccharides with different ratios

[0072]

[0073]

[0074] Obviously, the above embodiments are merely examples for clear explanation and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived from these are still within the protection scope of the invention.

Claims

1. A composition of probiotics and prebiotics, Features: The probiotics include Lactobacillus johnsonii, the prebiotics include xylooligosaccharides and isomaltooligosaccharides, and the mass ratio of the xylooligosaccharides to isomaltooligosaccharides is (0.5-2.5):(0.5-2.5).

2. The composition according to claim 1, Features: The mass ratio of the xylooligosaccharide to the isomaltooligosaccharide is (0.5-1.5):(1.5-2.5).

3. The composition according to claim 1, Features: The viable count of Lactobacillus johnsonii is (1-5)×10 5 CFU / mL.

4. Use of the composition according to any one of claims 1 to 3 in the preparation of a product for preventing obesity.

5. The use according to claim 4, Features: The obesity is obesity induced by a high-fat diet.

6. The use according to claim 4, Features: The obesity prevention product is food or medicine.

7. The use according to claim 6, Features: The food includes health food and special medical purpose formula food.

8. A special medical formula food for preventing obesity, Features: The invention comprises the composition according to any one of claims 1 to 3.

9. The special medical purpose formula food according to claim 8, Features: Also included are food-acceptable excipients.

10. A drug for preventing obesity. Features: The invention comprises the composition according to any one of claims 1 to 3.

11. The drug according to claim 10, Features: The drug is taken in through the digestive tract.

12. Use of the composition according to any one of claims 1 to 3 in the preparation of a product for preventing non-alcoholic fatty liver disease.

13. Use of the composition according to any one of claims 1 to 3 in the preparation of a product for preventing hyperlipidemia.

14. Use of the composition according to any one of claims 1 to 3 in the preparation of a product for increasing high-density lipoprotein cholesterol in serum.

15. Use of the composition according to any one of claims 1 to 3 in the preparation of a product for reducing total cholesterol, triglycerides or low-density lipoprotein cholesterol in serum.

Citation Information

Patent Citations

  • Symbiotic composition for reducing blood lipid and preparation and application of symbiotic composition

    CN108295097A

  • Oligosaccharide probiotic composition and preparation method thereof

    CN113575963A

  • Lactobacillus johnsonii LS04 and application of lactobacillus johnsonii LS04 in preparation of fat-reducing and weight-losing products

    CN115895971A

  • Lactobacillus johnsonii hfi 108 having blood cholesterol level lowering and Anti-obesity activity

    KR1020100010015A